A
High ConfidenceREVEAL: Effects of Anacetrapib on Atherosclerotic Vascular Disease
Bowman L, et al (HPS3/TIMI55-REVEAL) • N Engl J Med
Key Finding
Raising HDL pharmacologically provides modest cardiovascular benefit.
Original title: “Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease”
Plain English Summary
Large trial of CETP inhibitor showing modest cardiovascular benefit despite raising HDL.
Paradigm Relevance
How this study applies to different clinical perspectives:
Standard Medical
RelevantConventional clinical guidelines used by most doctors
Research Consensus
RelevantCurrent scientific understanding, often ahead of guidelines
Metabolic Optimization
RelevantProactive targets for optimal health, not just disease absence
Study Details
- Type
- Landmark Study
Related Biomarkers
HDL CHOLESTEROL